MedTrace Logo

Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma

NCT00245089 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2013-08-12

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving vincristine, dactinomycin, and cyclophosphamide together works in treating patients with embryonal rhabdomyosarcoma.

Conditions

  • Sarcoma

Interventions

BIOLOGICAL

dactinomycin

DRUG

cyclophosphamide

DRUG

vincristine sulfate

Sponsors & Collaborators

  • Japan Rhabdomyosarcoma Study Group

    lead OTHER

Principal Investigators

  • Hajime Hosoi · Kyoto Prefectural University of Medicine

  • Ryoji Hanada, MD · Saitama Children's Medical Center

  • Keizo Horibe, MD, PhD · National Hospital Orgnization Nagoya Medical Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2011-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00245089 on ClinicalTrials.gov